|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 1.18 Billion
|
|
Market Size (2030)
|
USD 2.03 Billion
|
|
CAGR (2025-2030)
|
9.44%
|
|
Fastest Growing Segment
|
Brain Tumours
|
|
Largest Market
|
Mid-West
|
Market Overview
United States Veterinary
Stereotactic Radiosurgery System Market was valued at USD 1.18 Billion in 2024
and is expected to reach USD 2.03 Billion by 2030 with a CAGR of 9.44%. The United
States Veterinary Stereotactic Radiosurgery System Market is witnessing robust
growth driven by increased incidence of cancer among companion animals and
heightened demand for precise, non-invasive treatment options. Rising awareness
among pet owners about advanced therapeutic alternatives has led to higher
acceptance of radiosurgery solutions, especially for treating brain, nasal, and
spinal tumors in pets. According to the American Veterinary Medical
Association (AVMA), nearly 1 in 4 dogs will develop cancer at some stage, with
50% of dogs over the age of 10 succumbing to cancer. This alarming
trend has accelerated investments in sophisticated veterinary technologies,
making radiosurgery systems an essential component in oncology-focused
veterinary practices.
Technological progress in veterinary medical devices
is shaping new trends in the market. The adoption of linear accelerator
(LINAC)-based systems, capable of delivering highly targeted radiation, is
expanding rapidly due to their clinical precision and ability to reduce
treatment sessions. Innovations like image-guided radiotherapy (IGRT) and
motion management systems are enhancing treatment accuracy and outcomes.
Emerging solutions such as Proton Beam Radiation Therapy (PBRT) and Flash
Radiation Therapy are gaining interest for their potential to treat tumors more
effectively while sparing healthy tissues. The increasing integration of
software-driven planning tools and AI-assisted diagnostics in radiosurgery
workflow is also improving case management and expanding the scope of treatable
conditions.
Despite the market's promising outlook, several
challenges remain. High equipment costs and the limited availability of
specialized treatment centers pose barriers to adoption. Many small and
mid-sized veterinary practices are constrained by capital investment
limitations, preventing them from offering advanced radiotherapy services.
Regulatory requirements for the installation and operation of such equipment
further add to the complexity. Moreover, there is a shortage of veterinary
oncologists and radiation therapy-trained personnel, which restricts the number
of facilities that can efficiently run stereotactic radiosurgery units.
Addressing these structural gaps will be vital for expanding access and
sustaining market growth across the United States.
Key Market Drivers
Rising
Pet Ownership
Rising pet ownership in the United States
significantly drives the growth of the Veterinary Stereotactic Radiosurgery
System Market. According to the American Pet Products Association (APPA),
approximately 66% of U.S. households representing over 86 million homes owned a
pet in 2023, with dogs and cats being the most common. As pets are
increasingly considered integral family members, their owners are prioritizing
specialized and high-quality medical care, including advanced cancer treatment
options. This cultural shift is fueling demand for cutting-edge, non-invasive
treatments like stereotactic radiosurgery (SRS), which offers precision in
targeting tumors such as brain, nasal, and spinal cancers while minimizing
risks and recovery times.
The U.S. market is also influenced by the steady
increase in veterinary healthcare spending. The APPA reported that
Americans spent over USD 38 billion on veterinary care and related services in
2023, a figure expected to grow with rising awareness about pet oncology and
available treatment innovations. This financial commitment reflects the
readiness of pet owners to invest in advanced procedures that improve their
pets' quality of life and survival rates. As a result, veterinary clinics and
specialty hospitals across the country are incorporating technologies like SRS
to remain competitive and meet the evolving expectations of pet parents seeking
the best possible outcomes.
Advancements
in Veterinary Oncology
Advancements in veterinary oncology are significantly
propelling the growth of the United States Veterinary Stereotactic Radiosurgery
System Market. As veterinary oncology evolves, treatments for various cancers
in animals have become more effective and accessible. Stereotactic radiosurgery
(SRS), which precisely targets tumors with minimal damage to surrounding
healthy tissues, is at the forefront of these innovations. The ability of SRS
to treat difficult-to-reach tumors, such as those in the brain or spine,
without the need for traditional invasive surgery has made it an attractive
option for veterinary oncologists. These advancements are particularly
important as more animals, especially pets, are diagnosed with various types of
cancer, driving the demand for specialized treatment options.
Cancer is a leading cause of death among older pets. According
to the American Veterinary Medical Association (AVMA), one in four dogs will be
diagnosed with cancer in their lifetime, and this rate increases to nearly one
in two for dogs over 10 years old. Similarly, cancer accounts for almost half
of the deaths in pets over 10 years of age. These statistics highlight
the critical need for effective cancer treatments in veterinary medicine.
Veterinary oncologists are increasingly adopting
cutting-edge technologies and techniques in response to the rising incidence of
cancer among pets. This shift is supported by improved diagnostic capabilities,
including advanced imaging systems that aid in tumor localization, making SRS a
more viable treatment option. The continuous development of radiosurgery
systems and the integration of artificial intelligence in treatment planning
have further enhanced the precision and effectiveness of these therapies. As a
result, veterinary clinics and hospitals are incorporating these advanced
technologies into their service offerings to provide better outcomes for pets
with cancer.
Rising
Incidence of Cancer in Pets
The increasing incidence of cancer in pets is a major
driver of the United States veterinary stereotactic radiosurgery (SRS) system
market. Companion animals are increasingly diagnosed with various forms of
cancer such as lymphoma, mast cell tumors, and osteosarcoma, leading to a
greater demand for high-precision, non-invasive treatment options. SRS has
emerged as a leading modality by delivering targeted radiation doses to tumors
with minimal impact on surrounding healthy tissue, resulting in fewer side effects
and faster recovery times. This is especially valuable for treating tumors
located near vital organs or in anatomically sensitive areas.
According to the American
Veterinary Medical Association (AVMA), cancer is the leading cause of death in
older pets, with approximately 50% of dogs over the age of 10 likely to develop
cancer. The Veterinary Cancer Society also notes that nearly 6 million dogs and
a similar number of cats are diagnosed with cancer each year in the United
States. These statistics underline the urgent need for advanced oncology tools
and services within veterinary care.
As awareness of SRS's clinical benefits increases
among veterinary professionals and pet owners, adoption rates continue to rise.
The growing trust in SRS as an effective, low-risk therapy option is driving
investment in specialized treatment facilities and equipment, positioning the
technology as a cornerstone of modern veterinary oncology in the United States.
Download Free Sample Report
Key Market Challenges
Limited
Availability of Specialized Veterinary Oncologists
The United States Veterinary Stereotactic Radiosurgery
System Market faces a significant challenge due to the limited availability of
specialized veterinary oncologists. Stereotactic radiosurgery (SRS) requires
highly trained professionals capable of handling complex equipment and
diagnosing cancer in animals. These systems are intricate and demand expertise
not only in using advanced technology but also in understanding the specifics
of veterinary oncology, which differs significantly from human oncology. The
scarcity of skilled veterinary oncologists limits the effective use of
stereotactic radiosurgery systems in clinical practice, especially in regions
where veterinary oncology is still emerging as a specialized field.
The lack of sufficient training and education programs
for veterinary professionals further exacerbates this issue. While veterinary
schools are increasingly offering specialized courses, the demand for trained
oncologists outpaces the supply, making it difficult for veterinary clinics to
adopt SRS as a standard treatment option. In rural or less developed areas,
where access to specialized care is already limited, the situation is even more
pronounced. The financial constraints of veterinary clinics in these regions
also impact their ability to invest in advanced treatments like stereotactic
radiosurgery systems, which require significant capital and ongoing
maintenance.
The challenge of limited availability of skilled
professionals not only hinders the adoption of these systems but also affects
the overall quality of care animals receive. Without adequate expertise, the
potential benefits of stereotactic radiosurgery such as its precision and
non-invasive nature are diminished, leading to underutilization of the
technology.
Concerns
Over Efficacy and Safety
The United States Veterinary Stereotactic
Radiosurgery System Market faces significant challenges concerning the efficacy
and safety of these advanced treatment modalities. SRS systems, including Gamma
Knife, Linear Accelerators (LINAC), Pencil Beam Scanning Radiotherapy (PBRT),
and CyberKnife, are primarily utilized to treat various cancers in animals.
While these technologies offer non-invasive and precise radiation therapy,
concerns persist regarding their effectiveness across diverse animal
populations and the potential risks associated with their use.
A critical issue is the variability in treatment
outcomes. Factors such as tumor type, animal size, and overall health can
influence the success rates of SRS treatments. This variability necessitates
extensive research and clinical trials to establish standardized protocols and
identify which animals are most likely to benefit from SRS. Without robust
data, veterinarians may face challenges in recommending SRS as a viable
treatment option.
Safety concerns also play a pivotal role. While SRS is
designed to minimize damage to surrounding healthy tissues, there remains a
risk of adverse effects. Potential complications include radiation-induced side
effects, which can vary based on the animal's species, age, and health status.
Ensuring that veterinary professionals are adequately trained to operate SRS
equipment and monitor post-treatment effects is essential to mitigate these
risks.
The high costs associated with acquiring and
maintaining SRS equipment further complicate the situation. Many veterinary
practices, especially in emerging markets, may find it financially challenging
to invest in such advanced technologies. This financial barrier can limit
access to SRS treatments, particularly in regions with limited veterinary
oncology services.
Key Market Trends
Growing
Adoption of Non-Invasive Treatments
The increasing preference for non-invasive treatments
in veterinary care is a key trend driving the growth of the United States
Veterinary Stereotactic Radiosurgery System Market. With rising awareness about
animal welfare and advancements in veterinary medicine, pet owners and
veterinarians are increasingly opting for procedures that reduce the physical
trauma and recovery time associated with traditional surgical methods. Stereotactic
radiosurgery (SRS) represents a significant shift in the approach to treating
tumors in pets, offering a non-invasive alternative to conventional surgery.
SRS targets tumors with high precision, delivering radiation with minimal harm
to surrounding healthy tissues, which makes it an appealing choice for treating
brain and spinal tumors, particularly in older or high-risk animals.
The demand for non-invasive treatments is growing as
pets are considered more than just animals; they are seen as beloved family
members. Pet owners are more inclined to invest in medical solutions that
provide less discomfort and faster recovery for their pets. SRS provides these
advantages, allowing animals to recover with minimal pain and short
hospitalization, which is an attractive proposition for both pet owners and
veterinary professionals. The popularity of non-invasive treatments is further
fueled by their success in human medicine, where techniques like radiosurgery
and targeted radiation therapy have seen widespread use for treating tumors in
humans. As these methods become more well-known and accepted, the veterinary
industry has followed suit, recognizing the potential for improved patient
outcomes.
Veterinary clinics are adopting these advanced
technologies to meet the growing demand for high-quality, efficient care. The
rise in pet healthcare investments and the broader trend of minimizing
procedural invasiveness have created a favorable environment for the growth of
the veterinary stereotactic radiosurgery system market. This trend is expected
to continue as veterinary professionals increasingly embrace non-invasive
techniques to enhance treatment precision and improve the overall well-being of
pets.
Growing
Interest from Veterinary Educational Institutions
Veterinary educational institutions across the United
States are accelerating their integration of advanced cancer treatment
technologies such as stereotactic radiosurgery (SRS) to improve clinical
outcomes in companion animals. These institutions are not only investing in
state-of-the-art radiotherapy systems but also expanding specialized training
programs to support the next generation of veterinary oncologists. This trend
reflects a growing commitment to precision medicine in veterinary care, particularly
in the management of complex tumors that were once difficult to treat.
In September 2024, the LSU School
of Veterinary Medicine advanced its oncology capabilities by acquiring a Varian
Trilogy linear accelerator, enabling delivery of stereotactic radiotherapy and
intensity-modulated radiation therapy (IMRT) using RapidArc technology. This system
significantly enhances treatment precision and reduces sedation time for animal
patients. The University of Florida’s College of Veterinary Medicine
similarly upgraded its cancer treatment infrastructure with the addition of a
Varian Edge linear accelerator in 2021, enabling treatment of hard-to-reach
tumors previously considered inoperable.
According to the American College
of Veterinary Radiology (ACVR), a 2022 industry survey found that 59% of
veterinary oncology centers in the U.S. had access to IMRT capabilities, and
among those, 92% also performed stereotactic radiation therapy (SRT). This adoption
rate signals a nationwide shift toward integrating advanced radiation therapies
in veterinary practice. By embracing cutting-edge treatment modalities such as
SRS, U.S. veterinary schools and hospitals are aligning with rising
expectations from pet owners who demand high standards of care, while fostering
innovation in veterinary oncology and setting new benchmarks for clinical
excellence.
Segmental Insights
Product
Insights
Based
on the Product, LINAC (Linear Accelerator) systems emerged as the dominant
segment in the United States Veterinary Stereotactic Radiosurgery System
Market in 2024. This is due to its advanced capabilities in delivering
precise, high-dose radiation to target tumors in animals. LINAC systems are
favored for their ability to perform non-invasive treatments with minimal
damage to surrounding healthy tissues, making them particularly effective for
treating a variety of cancers in animals, including those located in
hard-to-reach areas. LINAC systems offer flexibility in treatment planning,
with the ability to adapt to different animal sizes and tumor types, making
them versatile for use in veterinary practices. Their high accuracy in
delivering radiation ensures that the therapeutic doses are precisely
administered, reducing the risk of side effects and enhancing treatment
efficacy. Furthermore, LINAC technology is widely recognized in human medicine,
which contributes to its adoption in veterinary oncology centers, as many
facilities already use these systems for human treatments, thus lowering the
initial investment barriers.
End
User Insights
Based on the End User, Veterinary
Hospitals emerged as the dominant segment in the United States Veterinary
Stereotactic Radiosurgery System Market in 2024. This growth can be attributed
to the increasing demand for advanced veterinary care and specialized treatment
options for animals. Veterinary hospitals are equipped with the infrastructure,
expertise, and resources necessary to integrate cutting-edge technologies like
SRS systems into their practices, offering highly specialized oncology services
for pets, particularly for complex cases such as cancer. These hospitals
typically house advanced diagnostic and imaging equipment, which is crucial for
the precise planning and execution of SRS treatments. The ability to provide
advanced, non-invasive treatments like stereotactic radiosurgery makes
veterinary hospitals attractive to pet owners seeking the best possible care
for their animals, especially for those with limited treatment options.
Moreover, the growing awareness of cancer treatment in pets, particularly among
affluent pet owners, has led to an increased preference for veterinary
hospitals that offer these sophisticated procedures.
Download Free Sample Report
Regional Insights
The Mid-West region
emerged as the dominant region in the United States Veterinary
Stereotactic Radiosurgery System Market in 2024. This is
due to a well-established veterinary healthcare infrastructure and a high
concentration of specialized oncology centers. States such as Illinois, Ohio,
and Minnesota host leading veterinary teaching hospitals and research
institutions, which are early adopters of advanced technologies like
stereotactic radiosurgery systems. These institutions play a crucial role in
integrating cutting-edge cancer treatment protocols and serve as referral hubs
for complex cases across the region. The Mid-West also benefits from a strong
presence of veterinary equipment manufacturers and medical technology firms,
which facilitates easier access to the latest devices and technical support.
High awareness among pet owners in the region regarding advanced treatment
options, coupled with a willingness to invest in quality healthcare for
companion animals, supports sustained demand for radiosurgery systems. The
availability of trained veterinary oncologists and radiology experts further
strengthens the adoption rate of these systems.
Recent Developments
- In September 2024, LSU Vet Med advanced its veterinary
oncology capabilities with the acquisition of a Varian Trilogy linear
accelerator. This cutting-edge equipment allows for the delivery of advanced
stereotactic radiotherapy and intensity-modulated radiation therapy (IMRT) with
RapidArc technology. The system improves the precision of cancer treatments,
minimizes side effects, and significantly reduces sedation time for animal
patients, reflecting the increasing adoption of stereotactic radiosurgery systems
in veterinary care.
- In September 2024, Blue Pearl Veterinary
Hospital in Malvern, Pennsylvania, became one of the first veterinary clinics
worldwide to implement the CyberKnife system, an advanced technology for
treating cancer in animals. The CyberKnife is a unique radiation delivery
system that combines a linear accelerator with a robotic platform, allowing for
the precise administration of high-energy x-rays or photons for radiation
therapy. This breakthrough marks a significant advancement in veterinary
oncology, enabling more targeted and effective cancer treatments.
- In May 2024, Elekta launched its latest linear
accelerator, Evo*, which incorporates cutting-edge AI-powered high-definition
imaging. This CT-Linac system is capable of supporting both online and offline
adaptive radiation therapy, along with enhanced image-guided radiation
treatments. Its flexibility allows clinicians to tailor the most suitable
radiation therapy method for each individual patient, offering a significant
improvement in the precision and personalization of cancer care.
- In February 2024, Varian Medical Systems, Inc.
received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for
its TrueBeam and Edge radiotherapy systems equipped with the HyperSight imaging
solution. This milestone solidifies the role of cutting-edge radiotherapy
technologies in veterinary oncology, offering veterinary hospitals the tools
needed to treat complex cancers in pets with increased accuracy.
- In October 2023, Thrive Pet Healthcare expanded its
network to over 380 locations across 37 U.S. states with the launch of Thrive
Pet Healthcare Specialists in Hoffman Estates. The facility provides
round-the-clock emergency care for pets with critical conditions and specialty
services by appointment. This expansion highlights the increasing emphasis on
specialized, high-quality veterinary care, with a growing focus on advanced
oncology treatments such as stereotactic radiosurgery to address the rising incidence
of cancer in pets.
Key Market Players
- Avante
Health Solutions
- Accuray
Inc.
- Elekta
AB
- Varian
Medical Systems Inc.
- PetCure
Oncology
- Xstrahl
Inc.
- CVS
Group
- Medtronic
PLC
- Nanovi
AS
- Merck
& Co. Inc.
|
By Product
|
By Application
|
By End User
|
By Region
|
- Gamma Knife
- LINAC
- Proton Beam Radiation Therapy (PBRT)/ Flash-RT
- CyberKnife
|
- Brain Tumours
- Spinal Tumours
- Other Applications
|
- Veterinary Hospitals
- Veterinary Specialty Clinics
- Research and Academic Institutions
|
- North-East
- Mid-West
- West
- South
|
Report Scope:
In this report, the United
States Veterinary Stereotactic Radiosurgery System Market has been segmented
into the following categories, in addition to the industry trends which have
also been detailed below:
- United
States Veterinary Stereotactic Radiosurgery System Market, By Product:
o
Gamma
Knife
o
LINAC
o
Proton
Beam Radiation Therapy (PBRT)/ Flash-RT
o
CyberKnife
- United
States Veterinary Stereotactic Radiosurgery System Market, By Application:
o
Brain
Tumours
o
Spinal
Tumours
o
Other
Applications
- United
States Veterinary Stereotactic Radiosurgery System Market, By End User:
o
Veterinary
Hospitals
o
Veterinary
Specialty Clinics
o
Research
and Academic Institutions
- United
States Veterinary Stereotactic Radiosurgery System Market, By Region:
o
North-East
o
Mid-West
o
West
o South
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the United States Veterinary
Stereotactic Radiosurgery System Market.
Available Customizations:
United States Veterinary Stereotactic Radiosurgery System
Market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
United States Veterinary Stereotactic Radiosurgery System
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]